Dual treatment with both CD155 and CD73 blocking antibodies significantly slowed tumor growth compared to either antibody alone, or a PBS control group, demonstrating the efficacy of combined CD155 and CD73 targeting (Supplementary Fig. 12B, C). Here, NT5E is linked to neoplasm.